Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "IECC2023: New Targets for Cancer Therapies"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 15 October 2023 | Viewed by 484
Special Issue Editor
Interests: prostate cancer; breast cancer; bioinformatics; genomics; transcription; biomarkers
Special Issues, Collections and Topics in MDPI journals
Topical Collection in Cancers: Cancer Biomarkers
Special Issue in Cancers: Feature Paper in Section "Cancer Biomarkers" in 2022
Special Issue Information
This Special Issue will comprise selected papers from the proceedings of the 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies (IECC 2023) 16-30 March 2023, held on sciforum.net, an online platform for hosting scholarly e-conferences and discussion groups.
The focus of this conference is the translation of recent discoveries into new therapeutic targets for cancer therapies. Topics of interest include, but are not limited to:
- Translational cancer genomics and epigenomics;
- Emerging immunotherapy targets;
- Overcoming therapeutic hurdles in resistance and undruggable proteins.
There will be five specific sessions, each with an invited keynote speaker and chair and short proffered talks on the following:
Session 1: Genome-wide Approaches for Target Identification.
Session 2: Targeting Metastasis.
Session 3: Novel Immunotherapy Targets.
Session 4: Novel Approaches for ‘Undruggable’ Targets.
Session 5: Overcoming Therapeutic Resistance.
Selected papers that attract the most interest on the web or that provide a particularly innovative contribution will be selected for publication. These papers will be subjected to peer review and published with the aim of rapid and wide dissemination of research results, developments, and applications. We hope that this Conference Series will continue to grow in acceptance and recognition among potential participants, contributors, experts who want to disseminate their latest findings, and readers who seek information on new targets for cancer therapies.
Dr. Carlos S. Moreno
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.